Tesofensine

 

Topic mentions per year

Topic mentions per year

2007-2016
024620072016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Tesofensine (TE), an inhibitor of monoamine presynaptic reuptake, has produced twice the weight loss seen with currently marketed… (More)
Is this relevant?
2010
2010
Tesofensine is a (triple) reuptake inhibitor of noradrenaline, dopamine, and serotonin that is in development for the treatment… (More)
Is this relevant?
2010
2010
Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant weight loss in humans. The present study aimed… (More)
Is this relevant?
2010
2010
Tesofensine is a novel monoamine reuptake inhibitor that inhibits both norepinephrine, 5-HT, and dopamine (DA) reuptake function… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Effective therapeutic options for Alzheimer’s disease (AD) are limited and much research is currently ongoing. The high attrition… (More)
  • figure 1
  • figure 2
  • figure 3
  • table I
  • figure 4
Is this relevant?
2008
2008
BACKGROUND Weight-loss drugs produce an additional mean weight loss of only 3-5 kg above that of diet and placebo over 6 months… (More)
Is this relevant?
2008
2008
OBJECTIVE Tesofensine (TE) is a norepinephrine, dopamine, and serotonin reuptake inhibitor. We conducted a meta-analysis of TE's… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2008
2008
BACKGROUND AND PURPOSE Tesofensine is a centrally acting drug under clinical development for Alzheimer's disease, Parkinson's… (More)
Is this relevant?
2008
2008
OBJECTIVE To assess the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with advanced… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2007
2007
The changes of gene expression resulting from long-term exposure to monoamine antidepressant drugs in experimental animals are… (More)
Is this relevant?